These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34261797)

  • 1. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
    Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
    Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of
    Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
    Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
    Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
    Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
    Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
    Magee K; Marsh IR; Turek MM; Grudzinski J; Aluicio-Sarduy E; Engle JW; Kurzman ID; Zuleger CL; Oseid EA; Jaskowiak C; Albertini MR; Esbona K; Bednarz B; Sondel PM; Weichert JP; Morris ZS; Hernandez R; Vail DM
    PLoS One; 2021; 16(8):e0255798. PubMed ID: 34383787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
    Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
    Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hernandez R; Walker KL; Grudzinski JJ; Aluicio-Sarduy E; Patel R; Zahm CD; Pinchuk AN; Massey CF; Bitton AN; Brown RJ; Sondel PM; Morris ZS; Engle JW; Capitini CM; Weichert JP
    Commun Biol; 2019; 2():79. PubMed ID: 30820474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    O'Leary KA; Bates AM; Jin WJ; Burkel BM; Sriramaneni RN; Emma SE; Nystuen EJ; Sumiec EG; Ponik SM; Morris ZS; Schuler LA
    Breast Cancer Res; 2023 Jun; 25(1):68. PubMed ID: 37312163
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
    J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma.
    Li M; Liu D; Lee D; Cheng Y; Baumhover NJ; Marks BM; Sagastume EA; Ballas ZK; Johnson FL; Morris ZS; Schultz MK
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin α
    Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
    Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
    Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
    Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Characterization of
    Grudzinski JJ; Hernandez R; Marsh I; Patel RB; Aluicio-Sarduy E; Engle J; Morris Z; Bednarz B; Weichert J
    J Nucl Med; 2019 Nov; 60(11):1622-1628. PubMed ID: 30954941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade.
    Jagodinsky JC; Vera JM; Jin WJ; Shea AG; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarthy I; Allawi RH; Kim K; Harari PM; Sondel PM; Newton MA; Crittenden MR; Gough MJ; Miller JR; Ong IM; Morris ZS
    Sci Transl Med; 2024 Sep; 16(765):eadk0642. PubMed ID: 39292804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
    Lu Y; Houson HA; Gallegos CA; Mascioni A; Jia F; Aivazian A; Song PN; Lynch SE; Napier TS; Mansur A; Larimer BM; Lapi SE; Hanker AB; Sorace AG
    Breast Cancer Res; 2024 Jun; 26(1):104. PubMed ID: 38918836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor models.
    Kerr CP; Sheehan-Klenk J; Grudzinski JJ; Adam DP; Nguyen TPT; Ferreira CA; Bates AM; Jin WJ; Kwon O; Olson AP; Lin W; Hyun M; Jagodinsky JC; Powers M; Sriramaneni RN; Clark PA; Shea AG; Rojas HC; Choi C; Massey CF; Zangl LM; Pinchuk AN; Aluicio-Sarduy E; Kim K; Engle JW; Hernandez R; Bednarz BP; Weichert JP; Morris ZS
    bioRxiv; 2024 Jul; ():. PubMed ID: 39071353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
    Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
    Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.